Jennifer Watson
Family · Coeur D Alene, IDNPI 1750344834
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by CSL Behring at 58.6% of the total. 2025 is the largest year on record at $10,193, 7.6 times the $1,335 reported in 2021. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $49.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$12K
- Phadia US Inc.$2K
- AstraZeneca$2K
- GSK$1K
- Sanofi$682
- Takeda Pharmaceuticals U.S.A., Inc.$537
- plus $2K from 22 others
What the payments were for
- Consulting fees$8,59741%
- Speaking & faculty fees$1,2506%
- Travel & lodging$3,39416%
- Food & beverage$7,52736%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 38 | $12,189 |
| Phadia US Inc. | 4 | $1,913 |
| AstraZeneca | 70 | $1,887 |
| GSK | 102 | $1,155 |
| Sanofi | 49 | $682 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $537 |
| Regeneron Healthcare Solutions, Inc. | 13 | $294 |
| Biocryst US Sales Co., LLC | 8 | $249 |
| Novartis | 20 | $230 |
| Blueprint Medicines Corporation | 10 | $222 |
| Genentech USA, Inc. | 13 | $209 |
| Amgen(2 entities) | 8 | $169 |
| Lilly USA, LLC | 5 | $105 |
| Grifols USA, LLC | 6 | $104 |
| ADMA Biomanufacturing LLC | 4 | $99 |
| Pharming Healthcare, Inc. | 4 | $98 |
| Octapharma USA, Inc. | 3 | $92 |
| Pfizer | 5 | $86 |
| Alk-abello, Inc | 4 | $85 |
| Boehringer Ingelheim | 4 | $74 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| AbbVie | 3 | $53 |
| Verona Pharma, Inc. | 2 | $45 |
| Galderma Laboratories, L.p. | 1 | $29 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Incyte Corporation | 1 | $23 |
| Organon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,802 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 28 | $621,103 |
| NucalaMepolizumab | 35 | $123,861 |
| XolairOmalizumab | 12 | $32,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,713 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $18,377 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $16,265 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,695 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,180 |
| DuleraMometasone/Formoterol | 24 | $8,885 |
| Arnuity ElliptaFluticasone Furoate | 18 | $7,568 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $4,909 |
| Epinephrine | 16 | $3,781 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $3,416 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 13 | $2,689 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $12,189 | $621,10328 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,155 | $168,837122 claims |
| AstraZenecaBreztri Aerosphere | $1,887 | $16,26522 claims |
| Boehringer IngelheimSpiriva Respimat | $74 | $10,18020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.
Other family in Coeur D Alene
- Julie McCardellCoeur D Alene$10K
- Erika SullivanCoeur D Alene$8K
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.